Publication | Closed Access

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

Hematological MalignancyOncologyChronic Myeloid LeukaemiaHematologyMyeloid NeoplasiaMulticentre Stop ImatinibComplete Molecular RemissionMedicineRadiation OncologyCancer ResearchHealth Sciences